FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2280888958> ?p ?o ?g. }

• W2280888958 endingPage "e009586" @default.
• W2280888958 startingPage "e009586" @default.
• W2280888958 abstract "<h3>Objective</h3> To calculate sustainable generic prices for 4 tyrosine kinase inhibitors (TKIs). <h3>Background</h3> TKIs have proven survival benefits in the treatment of several cancers, including chronic myeloid leukaemia, breast, liver, renal and lung cancer. However, current high prices are a barrier to treatment. Mass production of low-cost generic antiretrovirals has led to over 13 million people being on HIV/AIDS treatment worldwide. This analysis estimates target prices for generic TKIs, assuming similar methods of mass production. <h3>Methods</h3> Four TKIs with patent expiry dates in the next 5 years were selected for analysis: imatinib, erlotinib, lapatinib and sorafenib. Chemistry, dosing, published data on per-kilogram pricing for commercial transactions of active pharmaceutical ingredient (API), and quotes from manufacturers were used to estimate costs of production. Analysis included costs of excipients, formulation, packaging, shipping and a 50% profit margin. Target prices were compared with current prices. Global numbers of patients eligible for treatment with each TKI were estimated. <h3>Results</h3> API costs per kg were $347–$746 for imatinib, $2470 for erlotinib, $4671 for lapatinib, and $3000 for sorafenib. Basing on annual dose requirements, costs of formulation/packaging and a 50% profit margin, target generic prices per person-year were $128–$216 for imatinib, $240 for erlotinib, $1450 for sorafenib, and $4020 for lapatinib. Over 1 million people would be newly eligible to start treatment with these TKIs annually. <h3>Conclusions</h3> Mass generic production of several TKIs could achieve treatment prices in the range of $128–$4020 per person-year, versus current US prices of $75161–$139 138. Generic TKIs could allow significant savings and scaling-up of treatment globally, for over 1 million eligible patients." @default.
• W2280888958 created "2016-06-24" @default.
• W2280888958 creator A5007611490 @default.
• W2280888958 creator A5019711864 @default.
• W2280888958 creator A5037475059 @default.
• W2280888958 creator A5040685455 @default.
• W2280888958 creator A5053725340 @default.
• W2280888958 creator A5058226785 @default.
• W2280888958 creator A5060462160 @default.
• W2280888958 creator A5062811133 @default.
• W2280888958 creator A5063643387 @default.
• W2280888958 creator A5071875382 @default.
• W2280888958 date "2016-01-01" @default.
• W2280888958 modified "2023-10-10" @default.
• W2280888958 title "Target prices for mass production of tyrosine kinase inhibitors for global cancer treatment" @default.
• W2280888958 cites W1974903851 @default.
• W2280888958 cites W2005202092 @default.
• W2280888958 cites W2048183287 @default.
• W2280888958 cites W2056729428 @default.
• W2280888958 cites W2057185004 @default.
• W2280888958 cites W2080889846 @default.
• W2280888958 cites W2112942078 @default.
• W2280888958 cites W2113482932 @default.
• W2280888958 cites W2135383133 @default.
• W2280888958 cites W2163848297 @default.
• W2280888958 cites W2281859527 @default.
• W2280888958 doi "https://doi.org/10.1136/bmjopen-2015-009586" @default.
• W2280888958 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4735306" @default.
• W2280888958 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26817636" @default.
• W2280888958 hasPublicationYear "2016" @default.
• W2280888958 type Work @default.
• W2280888958 sameAs 2280888958 @default.
• W2280888958 citedByCount "49" @default.
• W2280888958 countsByYear W22808889582016 @default.
• W2280888958 countsByYear W22808889582017 @default.
• W2280888958 countsByYear W22808889582018 @default.
• W2280888958 countsByYear W22808889582019 @default.
• W2280888958 countsByYear W22808889582020 @default.
• W2280888958 countsByYear W22808889582021 @default.
• W2280888958 countsByYear W22808889582022 @default.
• W2280888958 crossrefType "journal-article" @default.
• W2280888958 hasAuthorship W2280888958A5007611490 @default.
• W2280888958 hasAuthorship W2280888958A5019711864 @default.
• W2280888958 hasAuthorship W2280888958A5037475059 @default.
• W2280888958 hasAuthorship W2280888958A5040685455 @default.
• W2280888958 hasAuthorship W2280888958A5053725340 @default.
• W2280888958 hasAuthorship W2280888958A5058226785 @default.
• W2280888958 hasAuthorship W2280888958A5060462160 @default.
• W2280888958 hasAuthorship W2280888958A5062811133 @default.
• W2280888958 hasAuthorship W2280888958A5063643387 @default.
• W2280888958 hasAuthorship W2280888958A5071875382 @default.
• W2280888958 hasBestOaLocation W22808889581 @default.
• W2280888958 hasConcept C104863432 @default.
• W2280888958 hasConcept C121608353 @default.
• W2280888958 hasConcept C126322002 @default.
• W2280888958 hasConcept C143998085 @default.
• W2280888958 hasConcept C2777329042 @default.
• W2280888958 hasConcept C2777583451 @default.
• W2280888958 hasConcept C2778019345 @default.
• W2280888958 hasConcept C2778087573 @default.
• W2280888958 hasConcept C2778695046 @default.
• W2280888958 hasConcept C2778729363 @default.
• W2280888958 hasConcept C2779438470 @default.
• W2280888958 hasConcept C2779490328 @default.
• W2280888958 hasConcept C2779786085 @default.
• W2280888958 hasConcept C512399662 @default.
• W2280888958 hasConcept C530470458 @default.
• W2280888958 hasConcept C71924100 @default.
• W2280888958 hasConcept C98274493 @default.
• W2280888958 hasConceptScore W2280888958C104863432 @default.
• W2280888958 hasConceptScore W2280888958C121608353 @default.
• W2280888958 hasConceptScore W2280888958C126322002 @default.
• W2280888958 hasConceptScore W2280888958C143998085 @default.
• W2280888958 hasConceptScore W2280888958C2777329042 @default.
• W2280888958 hasConceptScore W2280888958C2777583451 @default.
• W2280888958 hasConceptScore W2280888958C2778019345 @default.
• W2280888958 hasConceptScore W2280888958C2778087573 @default.
• W2280888958 hasConceptScore W2280888958C2778695046 @default.
• W2280888958 hasConceptScore W2280888958C2778729363 @default.
• W2280888958 hasConceptScore W2280888958C2779438470 @default.
• W2280888958 hasConceptScore W2280888958C2779490328 @default.
• W2280888958 hasConceptScore W2280888958C2779786085 @default.
• W2280888958 hasConceptScore W2280888958C512399662 @default.
• W2280888958 hasConceptScore W2280888958C530470458 @default.
• W2280888958 hasConceptScore W2280888958C71924100 @default.
• W2280888958 hasConceptScore W2280888958C98274493 @default.
• W2280888958 hasIssue "1" @default.
• W2280888958 hasLocation W22808889581 @default.
• W2280888958 hasLocation W22808889582 @default.
• W2280888958 hasLocation W22808889583 @default.
• W2280888958 hasLocation W22808889584 @default.
• W2280888958 hasLocation W22808889585 @default.
• W2280888958 hasLocation W22808889586 @default.
• W2280888958 hasOpenAccess W2280888958 @default.
• W2280888958 hasPrimaryLocation W22808889581 @default.
• W2280888958 hasRelatedWork W2002364528 @default.
• W2280888958 hasRelatedWork W2006912785 @default.
• W2280888958 hasRelatedWork W2007870311 @default.

• next